<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500290</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-AAS-2014-01</org_study_id>
    <nct_id>NCT02500290</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Switching Antiplatelet</brief_title>
  <official_title>Antiplatelet Therapy in Acute Coronary Syndrome (ACS). Safety and Efficacy of Switching Antiplatelet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Network for Design and Translation of Advanced Therapies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe antiplatelet therapy in ACS in Andalusia and make an assessment
      of efficacy and safety of hospital use Prasugrel / ticagrelor vs. Clopidogrel and Prasugrel
      switching to / ticagrelor patients pretreated with clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of acute coronary syndrome has changed in recent years as reflected in the new
      Clinical Practice Guidelines of the European Society of Cardiology for the management of ACS
      with or without ST segment elevation, with the development and increased accessibility of the
      angiography and percutaneous coronary intervention and the arrival of the new antiplatelet
      (Prasugrel and Ticagrelor).

      The ACS encompasses several clinical entities where dual antiplatelet therapy remains the
      basis of antiplatelet therapy and one of the mainstays of treatment. But the emergence of
      Prasugrel and Ticagrelor have changed the classical management with aspirin plus clopidogre
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Actual">February 21, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>type of antiplatelet were used</measure>
    <time_frame>12 months</time_frame>
    <description>There are the following therapeutic groups:
Clopidogrel; Prasugrel; Ticagrelor; Switching to Prasugrel ; Switching toTicagrelor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ischemic events after ACS during hospitalization</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Ischemic event is defined as the combined end point of stroke, reinfarction, stent thrombosis, restenosis and stent injury retreat previously treated
1. thrombotic complications: stroke, stent restenosis, retreat of the culprit vessel, stent thrombosis, CVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total rate of hemorrhage and severity thereof under TIMI9 and BARC15 classification. Also it included as a safety endpoint all-cause mortality.</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>bleeding complications: BARC, TIMI classification, transfusions, major bleedingbleeding complications: BARC, TIMI classification, transfusions, major bleeding</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Acute coronary syndrome</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with acute coronary syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to the Coronary Care Unit at the time defined with an initial
             diagnosis of ACS.

        Exclusion Criteria:

          -  Myocarditis, Takotsubo syndrome, pulmonary thromboembolism.

          -  Secondary MI or type 2, caused by an increase in demand or decrease oxygen (anemia,
             tachycardia, hypotension, heart failure, etc.). 11

          -  Patients under 18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Almedro Delia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Puerto Real</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Antequera</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

